Immunsuppressiva zur Verhinderung von Absto?ungsreaktionen nach allogenen Hornhauttransplantationen

详细信息    查看全文

• 作者：T. Lapp (1)
  P. Maier (1)
  F. Birnbaum (2)
  G. Schlunck (1)
  T. Reinhard (1)
  
• 关键词：Makrolide ; Ciclosporin?A ; Sanglifehrin?A ; Immunophiline ; Angeborenes Immunsystem ; Macrolides ; Cyclosporin A ; Sanglifehrin A ; Immunophilins ; Innate immune system
• 刊名：Der Ophthalmologe
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：111
• 期：3
• 页码：270-282
• 全文大小：835 KB
• 参考文献：1. Maguire MG, Stark WJ, Gottsch JD et al (1994) Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 101:1536-547 CrossRef
  2. Schrage N, Reinhard PDT, Seitz B et al (2011) Leistungsbericht der Deutschen Hornhautbanken 2009. Ophthalmologe 108:278-80 CrossRef
  3. Williams KA, Muehlberg SM, Lewis RF, Coster DJ (1995) How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye (Lond Engl) 9(Pt 2):219-27
  4. Williams KA, Muehlberg SM, Lewis RF, Coster DJ (1995) Graft survival after corneal transplantation: role of factors with the potential for recipient presensitisation. The Australian Corneal Graft Registry (ACGR). Transplant Proc 27:2141-142
  5. Birnbaum F, Jehle T, Schwartzkopff J et al (2008) Basiliximab following penetrating risk-keratoplasty -a prospective randomized pilot study. Klin Monatsbl Augenheilkd 225:62-5 CrossRef
  6. Mayer K, Birnbaum F, Reinhard T et al (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88:915-19 CrossRef
  7. Birnbaum F, B?hringer D, Sokolovska Y et al (2005) Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation 79:964-68 CrossRef
  8. Birnbaum F, Mayweg S, Reis A et al (2009) Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond Engl) 23:2063-070
  9. Birnbaum F, Schwartzkopff J, Scholz C et al (2007) The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model. Eye (Lond Engl) 21:1516-523
  10. Birnbaum F, Reis A, B?hringer D et al (2006) An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 81:767-72 CrossRef
  11. Ziaei M, Sharif-Paghaleh E, Manzouri B (2012) Pharmacotherapy of corneal transplantation. Expert Opin Pharmacother 13:829-40 CrossRef
  12. Niederkorn JY, Larkin DFP (2010) Immune privilege of corneal allografts. Ocul Immunol Inflamm 18:162-71 CrossRef
  13. Anshu A, Price MO, Price FW Jr (2012) Risk of corneal transplant rejection significantly reduced with Descemet’s membrane endothelial keratoplasty. Ophthalmology 119:536-40 CrossRef
  14. Cunnusamy K, Chen PW, Niederkorn JY (2010) Paradigm shifts in the role of CD4+T cells in keratoplasty. Discov Med 10:452-61
  15. Slegers TP, Rooijen N van, Rij G van, Gaag R van der (2000) Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes. Curr Eye Res 20:322-24 CrossRef
  16. Slegers TP, Torres PF, Broersma L et al (2000) Effect of macrophage depletion on immune effector mechanisms during corneal allograft rejection in rats. Invest Ophthalmol Vis Sci 41:2239-247
  17. Slegers TPAM, Broersma L, Rooijen N van et al (2004) Macrophages play a role in the early phase of corneal allograft rejection in rats. Transplantation 77:1641-646 CrossRef
  18. Reinhard T, B?cking A, Pomjanski N, Sundmacher R (2002) Immune cells in the anterior chamber of patients with immune reactions after penetrating keratoplasty. Cornea 21:56-1 CrossRef
  19. Flynn TH, Mitchison NA, Ono SJ, Larkin DFP (2008) Aqueous humor alloreactive cell phenotypes, cytokines and chemokines in corneal allograft rejection. Am J Transplant 8:1537-543 CrossRef
  20. Birnbaum F, Reis A, Reinhard T (2007) Topical immunosuppressives after penetrating keratoplasty. Ophthalmologe 104:381-87 CrossRef
  21. Riad M, Mogos M, Thangathurai D, Lumb PD (2002) Steroids. Curr Opin Crit Care 8:281-84 CrossRef
  22. Barrett AJ, Rezvani K, Solomon S et al (2003) New developments in allotransplant immunology. Hematol Am Soc Hematol Educ Program 350-71
  23. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-52 CrossRef
  24. Reis A, Birnbaum F, Reinhard T (2007) Systemic immunosuppressives after penetrating keratoplasty. Ophthalmologe 104:373-80 CrossRef
  25. King WJ, Comer RM, Hudde T et al (2000) Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 70:1225-233 CrossRef
  26. Rayner SA, King WJ, Comer RM et al (2000) Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clin Exp Immunol 122:109-16 CrossRef
  27. Bourges JL, Lallemand F, Agla E et al (2006) Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol Vis 12:1461-466
  28. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ (2003) Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 29:103-07 CrossRef
  29. ?Peri- und postoperative Behandlungsempfehlungen bei perforierender Keratoplastik-der Sektion Kornea der DOG (n.d.). http://www.dog.org/wp-content/uploads/2010/02/Behandlungsempfehlungen-Keratoplastik.pdf
  30. Quinones MP, Estrada CA, Kalkonde Y et al (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 83:672-81 CrossRef
  31. Zhao Q (2010) Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 88:41-5 CrossRef
  32. Boesecke C, Pett SL (2012) Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS 7:456-62 CrossRef
  33. Maeda K, Das D, Nakata H, Mitsuya H (2012) CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs 17:135-45 CrossRef
  34. Ruderman EM (2012) Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxf Engl) 51(Suppl 6):vi37–vi43
  35. Upchurch KS, Kay J (2012) Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxf Engl) 51(Suppl 6):vi28–vi36
  36. Kampik D, Ali RR, Larkin DFP (2012) Experimental gene transfer to the corneal endothelium. Exp Eye Res 95:54-9 CrossRef
  37. Sin W-X, Li P, Yeong JP-S, Chin K-C (2012) Activation and regulation of interferon-β in immune responses. Immunol Res 53:25-0 CrossRef
  38. Kallen J, Sedrani R, Zenke G, Wagner J (2005) Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution. J Biol Chem 280:21965-197 CrossRef
  39. Martin Cabrejas LM, Rohrbach S, Wagner D et al (1999) Macrolide analogues of the novel immunosuppressant sanglifehrin: new application of the ring-closing metathesis reaction. Angew Chem Int Ed Engl 38:2443-446 CrossRef
  40. Sanglier JJ, Quesniaux V, Fehr T et al (1999) Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity. J Antibiot (Tokyo) 52:466-73
  41. Nicolaou KC, Xu J, Murphy F et al (1999) Total synthesis of sanglifehrin A. Angew Chem Int Ed Engl 38:2447-451 CrossRef
  42. Halestrap AP, Clarke SJ, Javadov SA (2004) Mitochondrial permeability transition pore opening during myocardial reperfusion -a target for cardioprotection. Cardiovasc Res 61:372-85 CrossRef
  43. Abraham RT, Wiederrecht GJ (1996) Immunopharmacology of rapamycin. Annu Rev Immunol 14:483-10 CrossRef
  44. Allen A, Zheng Y, Gardner L et al (2004) The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol (Baltim Md 1950) 172:4797-803
  45. Woltman AM, Schlagwein N, Kooij SW van der, Kooten C van (2004) The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells. J Immunol (Baltim Md 1950) 172:6482-489
  46. Zhang L-H, Liu JO (2001) Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle. J Immunol 166:5611-618
  47. Zenke G, Strittmatter U, Fuchs S et al (2001) Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J Immunol 166:7165-171
  48. Zhang LH, Youn HD, Liu JO (2001) Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53. J Biol Chem 276:43534-3540 CrossRef
  49. Hackstein H, Thomson AW (2004) Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4:24-4 CrossRef
  50. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324-37 CrossRef
  51. Macedo C, Turquist H, Metes D, Thomson AW (2012) Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 1:16 CrossRef
  52. Amodio G, Gregori S (2012) Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res 1:14 CrossRef
  53. Obermajer N, Kalinski P (2012) Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 1:15 CrossRef
  54. Riquelme P, Geissler EK, Hutchinson JA (2012) Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 1:17 CrossRef
  55. Yona S, Jung S (2010) Monocytes: subsets, origins, fates and functions. Curr Opin Hematol 17:53-9 CrossRef
  56. Sànchez-Tilló E, Wojciechowska M, Comalada M et al (2006) Cyclophilin A is required for M-CSF-dependent macrophage proliferation. Eur J Immunol 36:2515-524 CrossRef
  57. H?rtel C, Iblher P, Puzik A et al (2006) Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes. Scand J Immunol 63:26-4 CrossRef
  58. Steinschulte C, Taner T, Thomson AW et al (2003) Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells. J Immunol (Baltim Md 1950) 171:542-46
  59. Hackstein H, Steinschulte C, Fiedel S et al (2007) Sanglifehrin a blocks key dendritic cell functions in vivo and promotes long-term allograft survival together with low-dose CsA. Am J Transplant 7:789-98 CrossRef
  60. Immecke SN, Baal N, Wilhelm J et al (2011) The cyclophilin-binding agent sanglifehrin A is a dendritic cell chemokine and migration inhibitor. PLoS One 6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069092/ (Zugegriffen: 25. Juli 2013)
  61. Schwartzkopff J, Olivares Valdez L, Bredow L et al (2011) Sanglifehrin A promotes allograft survival in rat keratoplasty. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2684&sKey=a3eec449-ac9a-44c0-a3b8-b35afc120517&cKey=5d110dad-c9dd-445f-bf0c-913e43fec86d&mKey=%7B6F224A2D-AF6A-4533-8BBB-6A8D7B26EDB3-7D
  62. Schwartzkopff J, Olivares L, Bredow L et al (2011) Hemmung von dendritischen Zellen durch Sanglifehrin A verbessert das Transplantatüberleben nach Keratoplastik. http://www.abstracts.dog.org/abstracts/abstract.html?id=6
  63. O’Neill LAJ (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 5:549-63 CrossRef
  64. Sabatini DM, Lai MM, Snyder SH (1997) Neural roles of immunophilins and their ligands. Mol Neurobiol 15:223-39 CrossRef
  65. Cardenas ME, Sanfridson A, Cutler NS, Heitman J (1998) Signal-transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol 16:427-33 CrossRef
  66. Shimmura-Tomita M, Shimmura S, Satake Y et al (2013) Keratoplasty postoperative treatment update. Cornea 32(Suppl 1): S60–S64 CrossRef
  67. Perry HD, Doshi-Carnevale S, Donnenfeld ED et al (2006) Efficacy of commercially available topical cyclosporine A 0.05- in the treatment of meibomian gland dysfunction. Cornea 25:171-75 CrossRef
  68. Utine CA, Stern M, Akpek EK (2010) Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 18:352-61 CrossRef
  69. Pacharn P, Vichyanond P (2013) Immunomodulators for conjunctivitis. Curr Opin Allergy Clin Immunol 13:550-57 CrossRef
  70. Birnbaum F, Reis A, Reinhard T (2009) Long term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 28:715-16 (author reply 716) CrossRef
  71. Magalhaes OA, Marinho DR, Kwitko S (2013) Topical 0.03- tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol 97:1395-398 CrossRef
  72. Reinhard T, Reis A, Mayweg S et al (2002) Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study. Klin Monatsbl Augenheilkd 219:125-31 CrossRef
  73. Auw-H?drich C, Reinhard T (2009) Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe 106:635-38 CrossRef
  74. Kari O, Saari KM (2010) Updates in the treatment of ocular allergies. J Asthma Allergy 3:149-58
  75. Li XQ, Buch G, Otasevic L et al (2008) Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty. Ophthalmic Res 40:309-14 CrossRef
  76. Birnbaum F, Schwartzkopff J, Scholz C, Reinhard T (2007) Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model. Graefes Arch Clin Exp Ophthalmol 245:1717-721 CrossRef
  77. Zapata G, Racca L, Tau J, Berra A (2012) Topical use of rapamycin in herpetic stromal keratitis. Ocul Immunol Inflamm 20:354-59 CrossRef
  78. Knapp S, Bertelmann E, Hartmann C et al (2003) Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther 19:181-92 CrossRef
  79. Bertelmann E, Knapp S, Rieck P et al (2003) Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance. Ophthalmologe 100:696-01 CrossRef
  80. Pleyer U, Milani JK, Dukes A et al (1995) Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 36:52-1
  81. Ha?m-Boukobza S, Balabanian K, Teicher E et al (2013) Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients. J Hepatol 59:613-15 CrossRef
  82. Gilliam BL, Riedel DJ, Redfield RR (2011) Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med 9(Suppl 1):S9 CrossRef
  83. Bachelerie F, Ben-Baruch A, Burkhardt AM et al (2014) International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and Introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66:1-9 CrossRef
  84. Hall AV, Jevnikar AM (2003) Significance of endothelial cell survival programs for renal transplantation. Am J Kidney Dis 41:1140-154 CrossRef
  85. Romagnani P, Crescioli C (2012) CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 413:1364-373 CrossRef
  86. Reinhard T, Sundmacher R, Godehardt E, Heering P (1997) Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor. Ophthalmologe 94:496-00 CrossRef
  87. Reinhard T, M?ller M, Sundmacher R (1999) Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea 18:645-51 CrossRef
  88. Benelli U, Lepri A, Del Tacca M, Nardi M (1996) FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 12:425-31 CrossRef
  89. Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108:1838-844 CrossRef
  90. Reis A, Reinhard T, Sundmacher R et al (1998) A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 236:785-89 CrossRef
  91. Brattstr?m C, Tydén G, S?we J et al (1996) A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28:985-86
  92. Morris RE, Huang X, Gregory CR et al (1995) Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27:2068-069
  93. Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209-16 CrossRef
  94. Vu MD, Qi S, Xu D et al (1998) Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66:1575-580 CrossRef
  95. Chatel M-A, Larkin DFP (2010) Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 150:179-84 CrossRef
  96. Stanojlovic S, Schlickeiser S, Appelt C et al (2010) Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol 248:1447-456 CrossRef
  97. Reis A, Reinhard T, Voiculescu A et al (1999) Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 83:1268-271 CrossRef
  98. Wlodarczyk Z, Vanrenterghem Y, Kr?mer BK et al (2012) A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation. BMC Nephrol 13:68 CrossRef
  99. Polack FM (1965) Inhibition of immune corneal graft rejection by azathioprine (imuran). Arch Ophthalmol 74:683-89 CrossRef
  100. Pleyer U (2003) Immunomodulation in penetrating keratoplasty. Current status and perspectives. Ophthalmologe 100:1036-044 CrossRef
  101. Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 99:38-5 CrossRef
  102. Tabbara KF (2008) Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol 28:223-32 CrossRef
  103. Reis A, Megahed M, Reinhard T et al (2002) Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21:81-4 CrossRef
  104. Baspinar Y, Bertelmann E, Pleyer U et al (2008) Corneal permeation studies of everolimus microemulsion. J Ocul Pharmacol Ther 24:399-02 CrossRef
  105. Reis A, Megahed M, Reinhard T et al (2000) Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70:1397-401 CrossRef
  106. Vincenti F, Tedesco Silva H, Busque S et al (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant 12:2446-456 CrossRef
  
• 作者单位：T. Lapp (1)
  P. Maier (1)
  F. Birnbaum (2)
  G. Schlunck (1)
  T. Reinhard (1)
  
  1. Klinik für Augenheilkunde, Universit?tsklinikum Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Deutschland
  2. Augenklinik, Klinikum Bremen-Mitte, Bremen, Deutschland
  
• ISSN：1433-0423

文摘

In order to prevent rejection of an allogeneic corneal transplant after perforating (high risk) keratoplasty, active agents from different classes of pharmacological substances are used, as with solid organ transplantation. In addition to glucocorticoids, antiproliferative agents, small molecule inhibitors and antibodies, those belonging to the group of macrolides with their many derivatives represent an interesting class of substances in this context. As a supplement to cyclosporin A (CSA) the most successful macrolide in transplantation medicine, animal experiments are currently being carried out to test newer macrolide derivatives, such as sanglifehrin A (SFA). This overview describes the classes of drugs and modes of action of currently administered standard medications in the clinical routine and new developments are presented.